Activist Kaos Capital pushes governance overhaul at Capricor ahead of FDA Duchenne decision

Activist investor Kaos Capital has sent a letter to Capricor Therapeutics shareholders demanding a “governance reset.” The firm asks for a meeting to nominate two independent directors, create an M&A and strategic alternatives committee, and freeze non‑essential spending while seeking additional drug candidates to complement its Duchenne program.

The request comes just one day before the Food and Drug Administration’s deadline to rule on Capricor’s cell‑based therapy for Duchenne muscular dystrophy, adding pressure on the company’s board to respond quickly.

In separate news, Bristol Myers Squibb announced another step in its AI‑driven drug discovery strategy, building on a recent partnership with Nvidia to establish a large AI data center aimed at accelerating target identification.

The developments highlight ongoing activist activity in biotech and continued investment in AI technologies across larger pharma firms.